These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 31189741)
1. Efficacy and adverse reaction to different doses of atorvastatin in the treatment of type II diabetes mellitus. Jiang H; Zheng H Biosci Rep; 2019 Jul; 39(7):. PubMed ID: 31189741 [No Abstract] [Full Text] [Related]
2. A comparison of the effects of low- and high-dose atorvastatin on lipoprotein metabolism and inflammatory cytokines in type 2 diabetes: Results from the Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA) randomized trial. Soran H; Liu Y; Adam S; Siahmansur T; Ho JH; Schofield JD; Kwok S; Gittins M; France M; Younis N; Gibson JM; Durrington PN; Rutter MK J Clin Lipidol; 2018; 12(1):44-55. PubMed ID: 29246729 [TBL] [Abstract][Full Text] [Related]
3. Atorvastatin affects low density lipoprotein and non-high density lipoprotein cholesterol relations with apolipoprotein B in type 2 diabetes mellitus: modification by triglycerides and cholesteryl ester transfer protein. Kappelle PJ; Zwang L; Huisman MV; Banga JD; Sluiter WJ; Dallinga-Thie GM; Dullaart RP Expert Opin Ther Targets; 2009 Jul; 13(7):743-51. PubMed ID: 19505224 [TBL] [Abstract][Full Text] [Related]
4. Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes -- CORALL study. Wolffenbuttel BH; Franken AA; Vincent HH; J Intern Med; 2005 Jun; 257(6):531-9. PubMed ID: 15910557 [TBL] [Abstract][Full Text] [Related]
5. Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: effect of triglyceride reductions with atorvastatin. Le NA; Innis-Whitehouse W; Li X; Bakker-Arkema R; Black D; Brown WV Metabolism; 2000 Feb; 49(2):167-77. PubMed ID: 10690940 [TBL] [Abstract][Full Text] [Related]
6. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux. Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475 [TBL] [Abstract][Full Text] [Related]
7. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. Watts GF; Barrett PH; Ji J; Serone AP; Chan DC; Croft KD; Loehrer F; Johnson AG Diabetes; 2003 Mar; 52(3):803-11. PubMed ID: 12606523 [TBL] [Abstract][Full Text] [Related]
13. Protective effect of atorvastatin on oxidative stress in streptozotocin-induced diabetic rats independently their lipid-lowering effects. Aktay G; Gürsoy ŞÖ; Uyumlu U; Ünüvar S; İlhan N J Biochem Mol Toxicol; 2019 May; 33(5):e22295. PubMed ID: 30657622 [TBL] [Abstract][Full Text] [Related]
14. Common variation in cholesteryl ester transfer protein: relationship of first major adverse cardiovascular events with the apolipoprotein B/apolipoprotein A-I ratio and the total cholesterol/high-density lipoprotein cholesterol ratio. Kappelle PJ; Gansevoort RT; Hillege HJ; Wolffenbuttel BH; Dullaart RP; J Clin Lipidol; 2013; 7(1):56-64. PubMed ID: 23351584 [TBL] [Abstract][Full Text] [Related]
15. Metabolic Syndrome and Serum Liver Enzymes Level at Patients with Type 2 Diabetes Mellitus. Music M; Dervisevic A; Pepic E; Lepara O; Fajkic A; Ascic-Buturovic B; Tuna E Med Arch; 2015 Aug; 69(4):251-5. PubMed ID: 26543313 [TBL] [Abstract][Full Text] [Related]
16. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia. Diabetes Atorvastin Lipid Intervention (DALI) Study Group Diabetes Care; 2001 Aug; 24(8):1335-41. PubMed ID: 11473066 [TBL] [Abstract][Full Text] [Related]
17. High Dose of Atorvastatin for the Treatment of Contrast-Induced Nephropathy After Carotid Artery Stenting. Fu M; Dai W; Ye Y; Lu Q; He W Am J Ther; 2017; 24(6):e718-e722. PubMed ID: 26720167 [TBL] [Abstract][Full Text] [Related]
18. Action of atorvastatin in combined hyperlipidemia : preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. Guerin M; Lassel TS; Le Goff W; Farnier M; Chapman MJ Arterioscler Thromb Vasc Biol; 2000 Jan; 20(1):189-97. PubMed ID: 10634817 [TBL] [Abstract][Full Text] [Related]
19. Modulating effect of atorvastatin on paraoxonase 1 activity in type 2 diabetic Egyptian patients with or without nephropathy. Abdin AA; Hassanien MA; Ibrahim EA; El-Noeman Sel-D J Diabetes Complications; 2010; 24(5):325-33. PubMed ID: 19553142 [TBL] [Abstract][Full Text] [Related]
20. [Effects of puerarin on rats with type 2 diabetes mellitus]. Yang F; Dong XX; Guo Y Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2019 Jul; 35(4):355-358. PubMed ID: 31701722 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]